Cancer gene therapy using a survivin mutant adenovirus
We have constructed a replication-deficient adenovirus encoding a nonphosphorylatable Thr(34)→Ala mutant of the apoptosis inhibitor survivin (pAd-T34A) to target tumor cell viability in vitro and in vivo. Infection with pAd-T34A caused spontaneous apoptosis in cell lines of breast, cervical, prostat...
Salvato in:
| Pubblicato in: | J Clin Invest |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society for Clinical Investigation
2001
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC200953/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11581299/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI12983 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|